Published in Vaccines (Basel) on July 17, 2014
Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking. Front Immunol (2016) 0.75
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Biology of immune responses to vaccines in elderly persons. Clin Infect Dis (2008) 2.32
Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep (2009) 2.02
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis (2008) 1.60
Immunosenescence and HIV. Curr Opin Immunol (2012) 1.51
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS (2008) 1.23
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One (2010) 1.21
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine (2009) 1.21
Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol (2011) 1.19
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest (2012) 1.14
Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc (2012) 1.13
Therapeutic vaccines against HIV infection. Hum Vaccin Immunother (2012) 1.11
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis (2013) 1.07
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther (2007) 1.03
Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects. J Virol (2011) 1.01
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther (2005) 1.01
Control of viral rebound through therapeutic immunization with DermaVir. AIDS (2005) 0.99
Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology (2002) 0.99
DermaVir: a novel topical vaccine for HIV/AIDS. J Invest Dermatol (2005) 0.98
Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS (2011) 0.98
Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection. J Immunol (2012) 0.98
Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs (2013) 0.97
Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol (2012) 0.95
Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol (2004) 0.95
25 years after HIV discovery: prospects for cure and vaccine. Virology (2010) 0.94
Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine (2005) 0.94
Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine (2010) 0.92
Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One (2012) 0.92
HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS (2004) 0.92
Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients. Ethiop Med J (2012) 0.91
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis (2000) 0.91
Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res Hum Retroviruses (2000) 0.90
Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. AIDS (2011) 0.89
Experiences of young adults growing up with innate or early acquired HIV infection--a qualitative study. J Adv Nurs (2012) 0.88
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine (2011) 0.87
Premature immune senescence during HIV-1 vertical infection relates with response to influenza vaccination. J Allergy Clin Immunol (2013) 0.86
Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm (2010) 0.86
Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Hum Retroviruses (2013) 0.85
Therapeutic immunization for HIV. Springer Semin Immunopathol (2006) 0.83
A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine (2005) 0.82
Nanomedicine applications towards the cure of HIV. Nanomedicine (2012) 0.82
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. J Acquir Immune Defic Syndr (2013) 0.81
The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine (2011) 0.81
Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC). PLoS One (2013) 0.80
Premature B-cell senescence as a consequence of chronic immune activation. Hum Vaccin Immunother (2014) 0.80
Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses. Viral Immunol (2012) 0.79
T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Clin Diagn Lab Immunol (2000) 0.78
Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Hum Vaccin Immunother (2013) 0.77
Human natural killer cells in asymptomatic human immunodeficiency virus-1 infection. Intervirology (2000) 0.76